Barclays

Business

Qatar slashes stake in Barclays with £510mn share sale

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.…

Read More »
Business

Barclays reportedly working on cost-cutting, layoff plans

Barclays has had a tough few months with tumbling share prices and weak third-quarter results. Now, the British lender is…

Read More »
Business

Barclays picks OneMain, AmEx, others as Overweight stocks in a Neutral sector (NYSE:OMF)

MicroStockHub Barclays takes a neutral view of the U.S. consumer finance sector and initiates coverage of 22 stocks, including consumer…

Read More »
Business

Barclays hints at big cost cuts as margin pressure intensifies By Reuters

© Reuters. FILE PHOTO: A branch of Barclays Bank is seen, in London, Britain, February 23, 2022. REUTERS/Peter Nicholls/File Photo…

Read More »
Entertainment

Fidelity National Information upgraded to Overweight at Barclays (NYSE:FIS)

Tippapatt/iStock via Getty Images Barclays analyst Ramsey El-Assal upgraded Fidelity National Information Services (NYSE:FIS) to Overweight from Equal Weight on…

Read More »
Entertainment

RTX downgraded at Barclays, RBC on costly jet-engine recall (NYSE:RTX)

RTX (NYSE:RTX) was downgraded by analysts at both Barclays Capital and RBC Capital Markets after the aerospace and defense company…

Read More »
Entertainment

PG&E, Duke Energy, AEP and Pinnacle West top Barclays’ new utilities ratings

imaginima/iStock via Getty Images “It’s too soon to be bullish” on the U.S. power and utilities sector (NYSEARCA:XLU), but there…

Read More »
Entertainment

Barclays starts Fortrea at equal weight, sees near-term margins below peers (FTRE)

porcorex Barclays has initiated coverage of Fortrea (NASDAQ:FTRE) with a equal weight rating, stating that it sees the clinical research…

Read More »
Entertainment

Eli Lilly, Merck top pharma picks in Barclays Q2 preview

Dzmitry Dzemidovich While investors are bracing for yet another challenging quarter when earnings season kicks off for commercial-stage biopharma later…

Read More »
Entertainment

Barclays bullish on Biomea, Replimune, Syndax, Iovance for 2H 2023 (NASDAQ:BMEA)

Oli Scarff Barclays says it has chosen Biomea Fusion (NASDAQ:BMEA), Replimune (NASDAQ:REPL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Iovance Biotherapeutics (NASDAQ:IOVA) as…

Read More »
Back to top button